In 2015, the Company launched APIs production facilities in Shostka. Investments in this project amounted to $ 39 million. Farmak already has 20 proprietary substances in its portfolio and more than 20 are planned for years to come. The Company invests in its own production being in line with pharmaceutical standards and accounting for environmental aspects. Laboratories have been upgraded, and new approaches to synthesis (multistage synthesis, flow technologies in synthesis) have been used.
